Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Phase II Study to Test the Efficacy of AB928 (Dual Adenosine Receptor Antagonist) and AB122 (a PD1 Checkpoint Inhibitor) in Combination With Short Course Radiotherapy and Consolidation Chemotherapy for Rectal Cancer (PANTHER)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 18, 2022
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 18, 2022
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 25, 2022
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 3, 2022
Phase 1b/2 Open-Label Multicenter, Dose Optimization Clinical Study of Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination with Azacitidine or Decitabine in Patients With AML, MDS, or CMML
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 5, 2022
Doxycycline for Emphysema in People Living with HIV
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 9, 2022
Development of a Novel Web-based Social Reward Task to Test Engagement of the Reward System in Mid- and Late-Life Depression
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 19, 2022
A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced Solid Tumors Resistant or Refractory to Standard Therapies
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 9, 2022
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects with Advanced Solid Tumors (CHAMP-1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 17, 2022
Intra-Arterial (IA) Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma (ACPP) and Choroid Plexus Carcinoma (CPC) Prior to Second-Look Surgery
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 17, 2022